Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.47), $0.01 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $1.93 million versus the consensus estimate of $1.71 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.